^
    17h
    LncRNA IRAIN inhibits mantle cell lymphoma progression by inducing cell cycle arrest and apoptosis: an in vitro study. (PubMed, Sci Rep)
    Collectively, these findings suggest that IRAIN may participate in the regulation of proliferation, apoptosis, and cell cycle progression in MCL cells, potentially through modulation of LSD1. These results provide preliminary experimental evidence for further understanding the potential biological function of IRAIN in MCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • KDM1A (Lysine Demethylase 1A) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    2d
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)
    2d
    BGB-11417-108: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (clinicaltrials.gov)
    P1/2, N=258, Recruiting, BeOne Medicines | N=56 --> 258 | Trial completion date: Dec 2027 --> Nov 2032 | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Nov 2029
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    2d
    A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. (PubMed, Sci Rep)
    POLA demonstrated robust single-agent antitumor activity in vivo, including in PDX models derived from patients with ibrutinib-resistant MCL. This signature likely reflects core pathways associated with POLA resistance and highlights potential novel therapeutic vulnerabilities. These findings strongly support further clinical investigation of POLA in combination with VEN as a BCL2- and MCL1-targeting therapeutic strategy in patients with R/R MCL and BCL2-positive R/R DLBCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD79B (CD79b Molecule)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Polivy (polatuzumab vedotin-piiq)
    5d
    A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Dec 2029
    Trial completion date
    |
    Imbruvica (ibrutinib)
    7d
    Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 51
    Enrollment closed • Enrollment change
    7d
    Preliminary Assessment of [18F]BL40 in PET/CT Scans (clinicaltrials.gov)
    P=N/A, N=10, Completed, British Columbia Cancer Agency | Not yet recruiting --> Completed | N=30 --> 10
    Trial completion • Enrollment change
    7d
    ICP-CL-00128: A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-na?ve mantle cell lymphoma (2025-524241-27-00)
    P2/3, N=40, Not yet recruiting, Innocare Pharma Inc.
    New P2/3 trial
    |
    CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • bendamustine • Truxima (rituximab-abbs)
    7d
    IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3? IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA. (2024-519790-19-00)
    P1/2, N=40, Recruiting, Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    bendamustine • Actemra IV (tocilizumab)
    8d
    Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma. (PubMed, Cureus)
    A diagnosis of statin-associated anti-HMGCR IMNM was established, and treatment with mycophenolate mofetil and intravenous immunoglobulin resulted in partial biochemical improvement...Further evaluation revealed mantle cell lymphoma with bone marrow involvement, IGH::CCND1 rearrangement, and TP53 deletion, consistent with high-risk disease. In this context, continued clinical and laboratory monitoring is appropriate in inflammatory myopathy, and new hematologic abnormalities warrant further evaluation.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 deletion
    9d
    TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, AstraZeneca | Trial primary completion date: Jul 2028 --> Oct 2028 | Trial completion date: Jul 2028 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
    12d
    IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas. (PubMed, Blood)
    Here, we investigated non-genetic mechanisms of ibrutinib resistance in marginal zone lymphoma (MZL) and their broader therapeutic implications. Pharmacological or genetic disruption of the IL-16/CD9/PI3K axis restored sensitivity to BTK inhibitors and R-CHOP and abrogated IL-16-induced signaling in primary CLL samples. In conclusion, an IL-16/CD9-driven, epigenetically regulated survival pathway represents one possible mechanism of resistance to BTK inhibitors and chemoimmunotherapy, supporting therapeutic targeting of this axis in refractory B-cell lymphomas.
    Journal • IO biomarker
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PLCG2 (Phospholipase C Gamma 2) • BCL2A1 (BCL2 Related Protein A1) • CD9 (CD9 Molecule) • IL16 (Interleukin 16)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab)